LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.79
−0.26%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.78
From 52W high−36.30%
Volume1.64M
Market cap$393.72M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.78
From 52W high
−36.30%
Volume
1.64M
Market cap
$393.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
43.9
MomentumView details →
1D Return
−0.26%
YTD Return
−0.79%
SummaryUpdated Jun 1, 2026
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company founded in 2014 and based in Bala Cynwyd, Pennsylvania. The company specializes in developing innovative treatments for rare diseases using its proprietary cell penetrating peptide technology platform. Since going public in 2014, Larimar has focused its efforts on advancing novel therapeutic approaches for conditions that currently have limited or no treatment options, with its lead program targeting Friedreich's ataxia, a devastating genetic disorder.
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP increased its stake in Larimar Therapeutics, Inc. by 143.8% during the first quarter, purchasing an additional 470,968 shares, according to a recent SEC filing.38d agoLarimar Therapeutics reported a net loss of $32.8 million for Q2 2026, with a diluted loss per share of $0.30, compared to a net loss of $26.2 million in Q2 2025.48d ago